This technology describes a biomarker and its application for diagnosing and predicting the prognosis of cholangiocarcinoma, utilizing the fucosylation levels and glycan structural changes of serum-derived exosomes from cholangiocarcinoma patients.
Existing methods for diagnosing cholangiocarcinoma have been limited by low accuracy and specificity due to non-specific biomarkers.
This biomarker demonstrates excellent specificity and sensitivity for cholangiocarcinoma, thereby enhancing the accuracy of diagnosis and prognosis prediction, and contributing to improved treatment efficiency and reduced mortality.
EP4632383A1
